We are making
early stage cancer
100,000x
easier to find
Early-stage cancer is notoriously difficult and expensive to find.
But it doesn’t have to be.
Using nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – we have developed an approach that is showing tremendous promise in finding stage I cancer, when it is most treatable.
Our initial focus is on early detection of difficult-to-treat cancers, such as ovarian and lung, which today are often found too late to save lives.
Our Approach
The Mercy Halo test is the first and only test for early cancer detection based on analysis of single extracellular vesicles (EVs), shed into the blood at a rate of 1,000 per cell per day and precisely traceable to their tissue of origin.
EVs FOR EARLY DETECTION
Recognizing the power of extracellular vesicles in early cancer detection is a recent phenomenon. But there is growing support for this unassuming microenvironment.
ABOUT MERCY
Our remarkable team runs the gamut from our young MD/PhD candidate co-founder with scientific imagination and no limits, to our seasoned advisors who have founded two of the most successful early cancer detection companies in history.
Our Approach
The Mercy Halo test is the first and only test for early cancer detection based on analysis of single extracellular vesicles (EVs), shed into the blood at a rate of 1,000 per cell per day and precisely traceable to their tissue of origin.
EVs FOR EARLY DETECTION
Recognizing the power of extracellular vesicles in early cancer detection is a recent phenomenon. But there is growing support for this unassuming microenvironment.
ABOUT MERCY
Our remarkable team runs the gamut from our young MD/PhD candidate co-founder with scientific imagination and no limits, to our seasoned advisors who have founded two of the most successful early cancer detection companies in history.
“Despite billions of dollars invested into companies pursuing various cfDNA-focused approaches, early stage detection of cancer and pre-cancer at clinically meaningful sensitivities remains elusive.
This is most likely because DNA in blood is an exceedingly poor marker for early detection. There just isn’t enough DNA that is reliably shed into the circulation from tumors which are not well vascularized.
Enter exosomes. Cancer cells shed exosomes with their cancer specific surface markers at far greater abundance than they shed limited quantities of DNA. Mercy’s novel approach enhances the specificity of cancer exosome detection by co-localization.”
Stanley Lapidus, Founder of Exact Sciences and Cytyc, Inventor of Cologuard and Thin Prep
Let’s Collaborate!
Please use the form below for questions or collaboration inquiries